


The Art and Science of Brief Psychotherapies *A Practitioner's Guide, Third Edition*

Edited by Mantosh J. Dewan, M.D.,
Brett N. Steenbarger, Ph.D., and Roger P. Greenberg, Ph.D.



Each chapter is thoroughly updated, and new chapters cover such topics as dialectical behavior therapy, multicultural practice, and mentalizing, as well as fresh approaches to intervention, such as telepsychiatry and Internet-based interventions.



2018 • 397 pages • ISBN 978-1-61537-079-5 • Paperback • \$87.00 • Item #37079

2018 • 397 pages • ISBN 978-1-61537-151-8 • eBook • \$70.00 • Item #37151

AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



www.appi.org
Email: appi@psych.org
Phone: 1-800-368-5777


AH1822A

Telepsychiatry and Health Technologies

A Guide for Mental Health Professionals

*Peter Yellowlees, MBBS, M.D., and
Jay H. Shore, M.D., M.P.H.*

This book is a practical, comprehensive, and evidence-based guide to patient-centered clinical care delivered in whole or in part by technological devices and applications. It describes basic technological concerns and emphasizes clinical issues and workflows. It is designed for psychiatrists, psychologists, and other mental health clinicians who seek to learn the modes, models, and methods of telepsychiatry.



2018 • 403 pages • ISBN 978-1-61537-085-6 • Paperback • \$69.00 • Item #37085

2018 • 403 pages • ISBN 978-1-61537-160-0 • eBook • \$55.00 • Item #37160

AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING




Order @ www.appi.org
Email: appi@psych.org
Phone: 1-800-368-5777

AH1806A

Office-Based Buprenorphine Treatment of Opioid Use Disorder, Second Edition

Edited by John A. Renner Jr., M.D.,
Petros Levounis, M.D., M.A., and
Anna T. LaRose, M.D.

This new edition of *Office-Based Buprenorphine Treatment* has been updated to reflect DSM-5 language, and two additional chapters have been included: one that addresses other pharmacotherapies useful in treating OUD, including methadone and naltrexone, and another that discusses OUD treatment specifically with regard to women's health and pregnancy.



2018 • 395 pages • ISBN 978-1-61537-083-2 • Paperback • \$79.00 • Item #37083

2018 • 395 pages • ISBN 978-1-61537-170-9 • eBook • \$63.00 • Item #37170

AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



Order @ www.appi.org
Email: appi@psych.org
Phone: 1-800-368-5777


AH1813A

Competency in Combining Pharmacotherapy and Psychotherapy Integrated and Split Treatment, Second Edition

Core Competencies in Psychotherapy

*Michelle B. Riba, M.D., M.S.,
Richard Balon, M.D., and
Laura Weiss Roberts, M.D., M.A.*

Series Editor: Glen O. Gabbard, M.D.



This book is designed to help psychiatrists at any stage of their career achieve competency in combining and coordinating pharmacotherapeutic and psychotherapeutic treatments for the benefit of their patients.

2018 • 175 pages • ISBN 978-1-61537-066-5 • Paperback • \$65.00 • Item #37066

2018 • 175 pages • ISBN 978-1-61537-180-8 • eBook • \$52.00 • Item #37180

AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



Order @ www.appi.org
Email: appi@psych.org
Phone: 1-800-368-5777

AH1805A



Searching for the perfect psychiatric career?

Let APA JobCentral help!

Manage Your Career

- Browse hundreds of active job listings!
- Create an account to save jobs, store multiple resumes and cover letters and communicate with employers through our internal messaging system.
- Set up multiple job alerts specifying your skills, interests and location to receive e-mails when employers post jobs that match your criteria.

Recruit for Open Positions

- Post your job in front of thousands of highly qualified psychiatrists.
- Cross promote your job listing in Psychiatric News.
- Search the anonymous resume database to find your ideal candidate.

AMERICAN
PSYCHIATRIC
ASSOCIATION



JOBCENTRAL
The Career Hub for Psychiatry

jobs.psychiatry.org

Child and Adolescent Psychiatrist - Outpatient Consultation Position

Full Time * Multiple locations in New Jersey

Hackensack Meridian Health is seeking a Board Certified/ Board Eligible Child and Adolescent Psychiatrist to join this growing team. With 4 hospitals in the top 10 ranking in New Jersey, this is an outstanding opportunity to join the area's largest healthcare network.

This opportunity is an outpatient consultation position working with the Pediatric Psychiatry Collaborative Hub Teams (social worker, case manager, data analyst), to provide consultation to Pediatricians and also directly to families and children. The ideal candidate will work collaboratively with Pediatricians in our statewide collaborative hubs to provide comprehensive patient care.

Learn more about Hackensack Meridian Behavioral Health Services at:

<https://www.hackensackmeridianhealth.org/services/behavioral-health/>

Highlights:

- Academic Affiliations with the new Seton Hall - Hackensack Meridian School of Medicine.
- Collaborations among multiple sites (statewide).
- Call is not required.
- Outpatient/Consultative setting.
- Competitive Salary.
- Comprehensive Benefits Package.

Duties and Responsibilities:

- Provide consultation support to Primary Care Pediatricians (PCPs) via telephone.
- Document consultations according to program guidelines.
- Provide screening and treatment services to patients referred by the PCPs according to program guidelines.
- Document treatment and screening services provided.
- Participate as required and as available in weekly Service Hub conference calls.
- Participate in educations of Pediatricians as determined in conjunction with the Program Co-Principal Investigators.

For immediate consideration, please submit your CV to:

Renee.Theobald@HackensackMeridian.org
or contact Renee Theobald at 732.751.3597.

As the area's premier provider, Hackensack Meridian Behavioral Health Services has provided comprehensive mental health and substance abuse services to the residents of Monmouth, Ocean, and Middlesex Counties for over forty years. Hackensack Meridian Health is dedicated to providing outstanding Behavioral Health Services to all members of our communities.

Hackensack Meridian Health is a leading not-for-profit health care network in New Jersey offering a complete range of medical services, innovative research, and life-enhancing care aiming to serve as a national model for changing and simplifying health care delivery through partnerships with innovative companies and focusing on quality and safety.

HACKENSACK MERIDIAN HEALTH
www.hackensackmeridianhealth.org
An Equal Opportunity Employer M/F/D/V

PSYCHIATRY OPPORTUNITIES New Jersey

Hackensack Meridian Health is a leading not-for-profit health care network in New Jersey offering a complete range of medical services, innovative research, and life enhancing care aiming to serve as a national model for changing and simplifying health care delivery through partnerships with innovative companies and focusing on quality and safety.

As the area's premier provider, **Hackensack Meridian Behavioral Health Services** has provided comprehensive mental health and substance abuse services to the residents of Monmouth, Ocean, and Middlesex Counties for over forty years. We are currently accepting applications for Psychiatrists to join our Mental Health and Addiction Interdisciplinary Teams in the following positions:

- Consultation Liaison Psychiatrist- Jersey Shore University Medical Center-Neptune, NJ
- Geriatric Psychiatry- Private Practice setting with Opportunity to teach Psychiatry Residents, Ocean County, NJ
- Staff Psychiatrist- Riverview Medical Center, Red Bank, NJ
- Medical Director of Adult Inpatient Unit- Riverview Medical Center, Red Bank, NJ
- Outpatient Psychiatry - Bay Behavioral Health-Old Bridge, NJ
- Staff Consultation- Hackensack Behavioral Health-Hackensack, NJ


In addition to our collegial work environment, we offer a highly competitive compensation package which includes: medical/dental plans, 403(b) retirement plan, and relocation assistance. **For immediate consideration, please contact Renee Theobald, at: Renee.Theobald@hackensackmeridian.org or call: 732 751-3597.**

HACKENSACK MERIDIAN HEALTH

www.hackensackmeridianhealth.org
An Equal Opportunity Employer M/F/D/V

Pocket Guide to Addiction Assessment and Treatment

Edited by Petros Levounis, M.D., M.A.,
Erin Zerbo, M.D., and Rashi Aggarwal, M.D.



The Pocket Guide to Addiction Assessment and Treatment is designed specifically to aid a wide range of clinicians, regardless of their training in addiction, to more confidently assess and treat this patient population. With an accessible, easily referenced format, this book serves as a go-to resource for general psychiatrists other practitioners involved in the addiction treatment field. And because all of the diagnostic discussions are DSM-5®-based, readers can be confident that they're getting the most relevant and up-to-date guidance on the topic.

2016 • 379 pages • ISBN 978-1-58562-512-3 • Paperback
\$65.00 • Item #62512

2016 • 379 pages • ISBN 978-1-58562-512-3 • eBook
\$52.00 • Item #37072

AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



www.appi.org
Email: appi@psych.org
Phone: 1-800-368-5777

AH1820A

Subscription and Business Information

The American Journal of Psychiatry, ISSN 0002-953X, is published monthly by the American Psychiatric Association.

The American Psychiatric Association does not hold itself responsible for statements made in its publications by contributors or advertisers. Unless so stated, material in *The American Journal of Psychiatry* does not reflect the endorsement, official attitude, or position of the American Psychiatric Association or of the Journal's Editorial Board.

Periodicals postage paid at Washington, DC, and additional mailing offices. POSTMASTER: Send address changes to *The American Journal of Psychiatry*, Circulation Department, American Psychiatric Association, 800 Maine Avenue, S.W., Suite 900, Washington, D.C. 20024.

Editorial Office

American Journal of Psychiatry
American Psychiatric Association
800 Maine Avenue, S.W., Suite 900
Washington, D.C. 20024
E-mail: ajp@psych.org

Customer Service

Phone: (800) 368-5777 (toll-free)
E-mail: appi@psych.org

APA Member Subscription Services

Phone: (888) 35-PSYCH (toll-free)

Subscriptions

Per year: individual \$333.00,
international \$500.00

Institutional subscriptions are tier priced. For institutional site license or pricing information, contact (202) 559-3729 or institutions@psych.org.

Additional subscription options, including single issues and student rates
Contact Customer Service

Advertising

Pharmaceutical Print and Online Advertising
Frank Cox, Kathleen Harrison, Tim Wolfinger
Pharmaceutical Media, Inc.
30 East 33rd Street
New York, NY 10016
Phone: (212) 904-0379
E-mail: twolfinger@pminy.com

Nonpharmaceutical and Online Sales

Eamon Wood
Pharmaceutical Media, Inc.
E-mail: ewood@pminy.com
(see address and phone above).

Permissions and Reprints

Material published in the journals of the American Psychiatric Association and American Psychiatric Association Publishing is protected by copyright and all rights are reserved. Material may not be reproduced in any form or by any means without written permission from the copyright owner. For permission to reproduce material published by APA, please visit <http://www.appi.org/customer-service/permissions> for more information. Permission can also be secured through the Copyright Clearance Center (www.copyright.com).

APA does not require that permission be obtained for the photocopying of isolated articles for nonprofit classroom or library reserve use; all fees associated with such permission are waived. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Requests for commercial distribution should be directed to (202) 609-7075.

For bulk reprints, please contact Jane Cha, (202) 609-7075; e-mail: jcha@psych.org.

Indexed in Abstracts for Social Workers, Academic Abstracts, Biological Abstracts, Chemical Abstracts, Chicago Psychoanalytic Literature Index, Cumulative Index to Nursing Literature, Excerpta Medica, Hospital Literature Index, Index Medicus, International Nursing Index, Nutrition Abstracts, Psychological Abstracts, Science Citation Index, Social Science Source, and Social Sciences Index.

Pages are produced by Sheridan Journal Services (Waterbury, VT) and printed by Sheridan NH (Hanover, NH) on acid-free paper effective with Volume 169, Number 1, January 2012.

© 2018 American Psychiatric Association.



Brief Summary: for full Prescribing Information and Patient Information, refer to package insert.

INDICATIONS AND USAGE

INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

WARNINGS AND PRECAUTIONS

Somnolence

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA concentrations may be higher and QT prolongation clinically significant. For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. For patients taking a strong CYP3A4 inhibitor, reduce the dose of INGREZZA to 40 mg once daily. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Somnolence
- QT Prolongation

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Variable and Fixed Dose Placebo-Controlled Trial Experience

The safety of INGREZZA was evaluated in 3 placebo-controlled studies, each 6 weeks in duration (fixed dose, dose escalation, dose reduction), including 445 patients. Patients were 26 to 84 years of age with moderate to severe tardive dyskinesia and had concurrent diagnoses of mood disorder (27%) or schizophrenia/schizoaffective disorder (72%). The mean age was 56 years. Patients were 57% Caucasian, 39% African-American, and 4% other. With respect to ethnicity, 28% were Hispanic or Latino. All subjects continued previous stable regimens of antipsychotics; 85% and 27% of subjects, respectively, were taking atypical and typical antipsychotic medications at study entry.

Adverse Reactions Leading to Discontinuation of Treatment

A total of 3% of INGREZZA treated patients and 2% of placebo-treated patients discontinued because of adverse reactions.

Common Adverse Reactions

Adverse reactions that occurred in the 3 placebo-controlled studies at an incidence of $\geq 2\%$ and greater than placebo are presented in Table 1.

Table 1: Adverse Reactions in 3 Placebo-Controlled Studies of 6-week Treatment Duration Reported at $\geq 2\%$ and $>$ Placebo

Adverse Reaction ¹	INGREZZA (n=262) (%)	Placebo (n=183) (%)
General Disorders		
Somnolence (somnolence, fatigue, sedation)	10.9%	4.2%
Nervous System Disorders		
Anticholinergic effects (dry mouth, constipation, disturbance in attention, vision blurred, urinary retention)	5.4%	4.9%
Balance disorders/fall (fall, gait disturbance, dizziness, balance disorder)	4.1%	2.2%
Headache	3.4%	2.7%
Akathisia (akathisia, restlessness)	2.7%	0.5%
Gastrointestinal Disorders		
Vomiting	2.6%	0.6%
Nausea	2.3%	2.1%
Musculoskeletal Disorders		
Arthralgia	2.3%	0.5%

¹ Within each adverse reaction category, the observed adverse reactions are listed in order of decreasing frequency.

Other Adverse Reactions Observed During the Premarketing Evaluation of INGREZZA

Other adverse reactions of $\geq 1\%$ incidence and greater than placebo are shown below. The following list does not include adverse reactions: 1) already listed in previous tables or elsewhere in the labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have clinically significant implications, or 5) which occurred at a rate equal to or less than placebo.

Endocrine Disorders: blood glucose increased

General Disorders: weight increased

Infectious Disorders: respiratory infections

Neurologic Disorders: drooling, dyskinesia, extrapyramidal symptoms (non-akathisia)

Psychiatric Disorders: anxiety, insomnia

During controlled trials, there was a dose-related increase in prolactin. Additionally, there was a dose-related increase in alkaline phosphatase and bilirubin, suggesting a potential risk for cholestasis.

DRUG INTERACTIONS

Drugs Having Clinically Important Interactions with INGREZZA

Table 2: Clinically Significant Drug Interactions with INGREZZA

Monoamine Oxidase Inhibitors (MAOIs)	
Clinical Implication:	Concomitant use of INGREZZA with MAOIs may increase the concentration of monoamine neurotransmitters in synapses, potentially leading to increased risk of adverse reactions such as serotonin syndrome, or attenuated treatment effect of INGREZZA.
Prevention or Management:	Avoid concomitant use of INGREZZA with MAOIs.
Examples:	isocarboxazid, phenelzine, selegiline
Strong CYP3A4 Inhibitors	
Clinical Implication:	Concomitant use of INGREZZA with strong CYP3A4 inhibitors increased the exposure (C_{max} and AUC) to valbenazine and its active metabolite compared with the use of INGREZZA alone. Increased exposure of valbenazine and its active metabolite may increase the risk of exposure-related adverse reactions.
Prevention or Management:	Reduce INGREZZA dose when INGREZZA is coadministered with a strong CYP3A4 inhibitor.
Examples:	itraconazole, ketoconazole, clarithromycin
Strong CYP2D6 Inhibitors	
Clinical Implication:	Concomitant use of INGREZZA with strong CYP2D6 inhibitors may increase the exposure (C_{max} and AUC) to valbenazine's active metabolite compared with the use of INGREZZA alone. Increased exposure of active metabolite may increase the risk of exposure-related adverse reactions.
Prevention or Management:	Consider reducing INGREZZA dose based on tolerability when INGREZZA is coadministered with a strong CYP2D6 inhibitor.
Examples:	paroxetine, fluoxetine, quinidine
Strong CYP3A4 Inducers	
Clinical Implication:	Concomitant use of INGREZZA with a strong CYP3A4 inducer decreased the exposure of valbenazine and its active metabolite compared to the use of INGREZZA alone. Reduced exposure of valbenazine and its active metabolite may reduce efficacy.
Prevention or Management:	Concomitant use of strong CYP3A4 inducers with INGREZZA is not recommended.
Examples:	rifampin, carbamazepine, phenytoin, St. John's wort ¹
Digoxin	
Clinical Implication:	Concomitant use of INGREZZA with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp).
Prevention or Management:	Digoxin concentrations should be monitored when co-administering INGREZZA with digoxin. Increased digoxin exposure may increase the risk of exposure related adverse reactions. Dosage adjustment of digoxin may be necessary.

¹ The induction potency of St. John's wort may vary widely based on preparation.

Drugs Having No Clinically Important Interactions with INGREZZA

Dosage adjustment for INGREZZA is not necessary when used in combination with substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5 based on *in vitro* study results.

OVERDOSAGE

Human Experience

The pre-marketing clinical trials involving INGREZZA in approximately 850 subjects do not provide information regarding symptoms with overdose.

Management of Overdosage

No specific antidotes for INGREZZA are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an overdose occurs, consult a Certified Poison Control Center (1-800-222-1222 or www.poison.org).

For further information on INGREZZA, call 84-INGREZZA (844-647-3992).



Distributed by:
Neurocrine Biosciences, Inc.
San Diego, CA 92130
INGREZZA is a trademark of Neurocrine Biosciences, Inc.
CP-VBZ-US-0203v2 09/17

ONE CAPSULE, ONCE DAILY¹

Convenient, once-daily dosing
without complex titration¹



- INGREZZA 80 mg provided rapid and significant reductions in TD severity by 6 weeks^{1,2}
—with continued reductions in TD severity through 48 weeks^{1,3}
- Generally well tolerated in clinical trials across a broad range of adult TD patients^{1,2}
- Selectively inhibits VMAT2, with no appreciable binding affinity for dopaminergic (including D2) or serotonergic receptors¹

VMAT2, vesicular monoamine transporter 2.

Not an actual patient

SIGN UP FOR NEWS AND UPDATES AT WWW.INGREZZAHCP.COM/REGISTER

Important Information

INDICATION & USAGE

INGREZZA[®] (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION

WARNINGS & PRECAUTIONS

Somnolence

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

ADVERSE REACTIONS

The most common adverse reaction ($\geq 5\%$ and twice the rate of placebo) is somnolence. Other adverse reactions ($\geq 2\%$ and $>$ placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the adjacent page for brief summary of Prescribing Information and visit www.INGREZZAHCP.com for full Prescribing Information.

REFERENCES: 1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc; 2017. 2. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. *Am J Psychiatry*. 2017;174(5):476-484. 3. Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-Year KINECT 3 extension study. *J Clin Psychiatry*. 2017;78(9):1344-1350.